在抗分类素CRPC中鉴定表观遗传单一疗法候选者
Buse Cevatemre1,2, İpek Bulut2, Ezgi Karyemez3
1School of Medicine, Koç University, İstanbul, Turkiye.
Turkish journal of biology = Turk biyoloji dergisi
|January 7, 2026
概括
抗高素的前列腺癌显示出对表观遗传抑制剂的脆弱性. 在CRPC模型中,4-Iodo-SAHA和SP2509克服了耐药性,并增强了多塞塔克塞尔治疗.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 塔克桑耐药性是治疗抗割前列腺癌 (CRPC) 的一个主要障碍.
- 表观遗传失调与化疗耐药性和癌症进展有关.
- 确定新的治疗点对于克服CRPC治疗耐药性至关重要.
研究的目的:
- 为了确定抗分类素抗性CRPC细胞系中的表观遗传脆弱性.
- 选针对表观遗传调节者的小分子,以检测它们对抗抗性CRPC的有效性.
- 评估已识别的化合物作为单一疗法或与纳税化合物结合的潜力.
主要方法:
- 利用一个小分子库,针对各种表观遗传调节器.
- 在对多塞和卡巴西抗性CRPC细胞系 (DU145,22Rv1) 上选的化合物.
- 评估了细胞活力,殖民地形成,细胞死亡,基因素修饰和蛋白质标;与多塞塔塞尔进行了组合测定.
主要成果:
- 抗分的CRPC细胞对多种表观遗传抑制剂敏感.
- 4-Iodo-SAHA (HDAC抑制剂) 和SP2509 (LSD1抑制剂) 显示出显著的细胞毒性和诱导细胞死亡.
- 这两种化合物都逆转了表观遗传修饰,增强了多塞塔克塞尔活性,并克服了对税的抗性.
结论:
- 在抗分类素CRPC中存在表观遗传漏洞.
- 4-Iodo-SAHA和SP2509是单一治疗或组合治疗的有希望的候选人.
- 这些药物可以增强多塞塔克塞尔的疗效,并克服CRPC的耐药性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


